Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

The first direct and selective interleukin-1 (IL-1) receptor antagonist, anakinra can be used alone or in combination with any of the other DMARDs, except those in the tumor necrosis factor (TNF ...

Key predictors of chronic pain following motor vehicle collisions include elevated levels of acute post-traumatic stress ...

Patients with moderate to severe asthma saw increases in FEV1 within 24 hours after taking a loading dose of rademikibart, ...